216 related articles for article (PubMed ID: 31606226)
41. Patient-reported outcome during radiotherapy for head and neck cancer: the use of different PRO questionnaires.
Steen-Olsen EB; Stormoen DR; Kristensen CA; Vogelius IR; Holländer-Mieritz C; Pappot H
Eur Arch Otorhinolaryngol; 2022 Aug; 279(8):4199-4206. PubMed ID: 35357578
[TBL] [Abstract][Full Text] [Related]
42. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors.
Beetz I; Schilstra C; Burlage FR; Koken PW; Doornaert P; Bijl HP; Chouvalova O; Leemans CR; de Bock GH; Christianen ME; van der Laan BF; Vissink A; Steenbakkers RJ; Langendijk JA
Radiother Oncol; 2012 Oct; 105(1):86-93. PubMed ID: 21632133
[TBL] [Abstract][Full Text] [Related]
43. Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiotherapy, and validation of the Taiwanese version of the xerostomia questionnaire.
Lin SC; Jen YM; Chang YC; Lin CC
J Pain Symptom Manage; 2008 Aug; 36(2):141-8. PubMed ID: 18395402
[TBL] [Abstract][Full Text] [Related]
44. Radiation-induced xerostomia: pathophysiology, clinical course and supportive treatment.
Guchelaar HJ; Vermes A; Meerwaldt JH
Support Care Cancer; 1997 Jul; 5(4):281-8. PubMed ID: 9257424
[TBL] [Abstract][Full Text] [Related]
45. Prospective study on health-related quality of life, oral mucositis and oral health on during treatment of head and neck cancer.
Karlsson C; Bohm N; Andersson JS; Finizia C; Almståhl A
BMC Oral Health; 2024 Jun; 24(1):697. PubMed ID: 38879501
[TBL] [Abstract][Full Text] [Related]
46. The effect of chewing sorbitol-sweetened gum on salivary flow and cemental plaque pH in subjects with low salivary flow.
Abelson DC; Barton J; Mandel ID
J Clin Dent; 1990; 2(1):3-5. PubMed ID: 2133392
[TBL] [Abstract][Full Text] [Related]
47. Reducing Late Dysphagia for Head and Neck Cancer Survivors with Oral Gel: A Feasibility Study.
Kaae JK; Spejlborg ML; Spork U; Bjørndal K; Eriksen JG
Dysphagia; 2020 Apr; 35(2):231-241. PubMed ID: 31073746
[TBL] [Abstract][Full Text] [Related]
48. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
[TBL] [Abstract][Full Text] [Related]
49. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
[TBL] [Abstract][Full Text] [Related]
50. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): A pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomia.
Blitzer GC; Glazer T; Burr A; Gustafson S; Ganz O; Meyers R; McDowell KA; Nickel KP; Mattison RJ; Weiss M; Chappell R; Rogus-Pulia NM; Galipeau J; Kimple RJ
Cytotherapy; 2023 Nov; 25(11):1139-1144. PubMed ID: 37589639
[TBL] [Abstract][Full Text] [Related]
51. Explorative study on quality of life in relation to salivary secretion rate in head and neck cancer patients treated with radiotherapy up to 2 years post treatment.
Almståhl A; Skoogh Andersson J; Alstad T; Fagerberg-Mohlin B; Finizia C
Int J Dent Hyg; 2019 Feb; 17(1):46-54. PubMed ID: 30113762
[TBL] [Abstract][Full Text] [Related]
52. Acupuncture for the prevention of radiation-induced xerostomia in patients with head and neck cancer.
Braga FP; Lemos Junior CA; Alves FA; Migliari DA
Braz Oral Res; 2011; 25(2):180-5. PubMed ID: 21537645
[TBL] [Abstract][Full Text] [Related]
53. Clinical effectiveness and safety of acupuncture in the treatment of irradiation-induced xerostomia in patients with head and neck cancer: a systematic review.
O'Sullivan EM; Higginson IJ
Acupunct Med; 2010 Dec; 28(4):191-9. PubMed ID: 21062848
[TBL] [Abstract][Full Text] [Related]
54. Grading xerostomia by physicians or by patients after intensity-modulated radiotherapy of head-and-neck cancer.
Meirovitz A; Murdoch-Kinch CA; Schipper M; Pan C; Eisbruch A
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):445-53. PubMed ID: 16839705
[TBL] [Abstract][Full Text] [Related]
55. The management of xerostomia in patients on haemodialysis: comparison of artificial saliva and chewing gum.
Bots CP; Brand HS; Veerman EC; Valentijn-Benz M; Van Amerongen BM; Nieuw Amerongen AV; Valentijn RM; Vos PF; Bijlsma JA; Bezemer PD; ter Wee PM
Palliat Med; 2005 Apr; 19(3):202-7. PubMed ID: 15920934
[TBL] [Abstract][Full Text] [Related]
56. The impact of radiotherapy on the quality of life in patients with early-stage clinical head and neck cancer.
Milecki J; Żmijewska-Tomczak M; Osmola K; Wierzbicka M
Otolaryngol Pol; 2021 May; 75(5):1-8. PubMed ID: 34552020
[TBL] [Abstract][Full Text] [Related]
57. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction.
Blitzer GC; Rogus-Pulia NM; Mattison RJ; Varghese T; Ganz O; Chappell R; Galipeau J; McDowell KA; Meyers RO; Glazer TA; Kimple RJ
Cytotherapy; 2022 May; 24(5):534-543. PubMed ID: 35183442
[TBL] [Abstract][Full Text] [Related]
58. Mastication, swallowing, and salivary flow in patients with head and neck cancer: objective tests versus patient-reported outcomes.
Vermaire JA; Raaijmakers CPJ; Verdonck-de Leeuw IM; Jansen F; Leemans CR; Terhaard CHJ; Speksnijder CM
Support Care Cancer; 2021 Dec; 29(12):7793-7803. PubMed ID: 34170408
[TBL] [Abstract][Full Text] [Related]
59. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.
Scarantino C; LeVeque F; Swann RS; White R; Schulsinger A; Hodson DI; Meredith R; Foote R; Brachman D; Lee N
J Support Oncol; 2006 May; 4(5):252-8. PubMed ID: 16724649
[TBL] [Abstract][Full Text] [Related]
60. Xerostomia: a day and night difference.
Dijkema T; Raaijmakers CP; Braam PM; Roesink JM; Monninkhof EM; Terhaard CH
Radiother Oncol; 2012 Aug; 104(2):219-23. PubMed ID: 22809589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
